CD274 and sarcoma: Further, in vitro studies showed that both PD-L1 antibodies and PD-L1 knockdown in tumor cells impaired sarcoma cell glycolysis and inhibited intracellular Akt/mTOR signaling, indicating the role of PD-L1 in modulating intracellular signaling pathway.